Weekly psoriasis therapy using intralesional fluorouracil*

https://doi.org/10.1016/S0190-9622(87)70175-3Get rights and content

We report the use of weekly intralesional fluorouracil for treatment of entire psoriatic papules and portions of larger psoriatic plaques. Eleven patients participated and responded, with an average of 4.2 cm2 clearing about the injection site in the treated lesions, in comparison with no improvement in the control lesions. We injected 1 ml of fluorouracil (50 mg/ml) to form an intradermal wheal of about 0.8 cm2. Each patient received one to three injections at 1- to 2-week intervals, with an average of two injections per patient. The earliest signs of improvement occurred at 2 weeks; maximum clearing was achieved usually about 4 weeks after treatment began. At 3-month follow-up, four of the nine patients who had favorable response to treatment remained substantially in remission. Toxic effects were limited to local hyperpigmentation in seven patients, slight irritation in two patients, and moderate irritation in one patient. No systemic toxic effects were shown. Weekly pulse doses of fluorouracil given intralesionally instead of topically can greatly speed up response to therapy and can produce similarly good results. Intralesional administration of fluorouracil is locally effective, is often of long-term benefit, and can be tolerated well.

References (4)

There are more references available in the full text version of this article.

Cited by (8)

  • Treatment of psoriasis. Part 1. Topical therapy and phototherapy

    2001, Journal of the American Academy of Dermatology
  • Mucocutaneous reactions to chemotherapy

    1999, Journal of the American Academy of Dermatology
  • Dermatologic therapy: December 1986 to December 1987

    1988, Journal of the American Academy of Dermatology
  • Intralesional therapy for psoriasis

    2013, Journal of Dermatological Treatment
  • Topical immunotherapy

    2004, Turkderm Deri Hastaliklari ve Frengi Arsivi
View all citing articles on Scopus
*

Supported by the Community Service Program of Kaiser Foundation Hospitals. Study protocol approved by the Kaiser Permanente Medical Care Program, Northern California Region, Institutional Review Board.

1

From the Department of Dermatology, Kaiser Permanente Medical Center.

View full text